← Leaderboards
Victor J Dzau
Brigham And Women'S Hospital
$23,122,586
Attributed
$23,122,586
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$46,497,952 · 13
By mechanism
R01$20,961,917 · 7
M01$20,832,557 · 1
P50$3,538,093 · 3
R37$1,162,317 · 1
P41$3,068 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingPathway InteractionsMyocardial InfarctionIn VivoHeartApoptosisCardiacStem CellsCellsInjuryIn VitroMyocardialGenesAdultSignal TransductionLaboratory MouseCardiac MyocytesAnimalsRepairedGene ExpressionResponseInfarctionInjection Of Therapeutic AgentProteins
Grant awards (67)
Sfrp2 induces in situ c-Kit cell differentiation into cardiomyocytes via Wnt11-Fzd5 mediated b-catenin inhibition$402,500
R01 · FY2021 · HL · contact PI
Sfrp2 induces in situ c-Kit cell differentiation into cardiomyocytes via Wnt11-Fzd5 mediated b-catenin inhibition$402,500
R01 · FY2020 · HL · contact PI
Novel Strategy for Enhancing miRNA As A Therapeutic for Cardiac Regeneration$397,500
R01 · FY2020 · HL · contact PI
Sfrp2 induces in situ c-Kit cell differentiation into cardiomyocytes via Wnt11-Fzd5 mediated b-catenin inhibition$401,458
R01 · FY2019 · HL · contact PI
Novel Strategy for Enhancing miRNA As A Therapeutic for Cardiac Regeneration$397,500
R01 · FY2019 · HL · contact PI
Sfrp2 induces in situ c-Kit cell differentiation into cardiomyocytes via Wnt11-Fzd5 mediated b-catenin inhibition$398,959
R01 · FY2018 · HL · contact PI
Novel strategy for Enhancing miRNA as a Therapeutic for Cardiac Regeneration$397,500
R01 · FY2018 · HL · contact PI
Novel strategy for Enhancing miRNA as a Therapeutic for Cardiac Regeneration$397,500
R01 · FY2017 · HL · contact PI
Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury$483,184
R01 · FY2015 · HL · contact PI
Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury$403,987
R01 · FY2014 · HL · contact PI
Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury$55,212
R01 · FY2014 · HL · contact PI
Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury$416,331
R01 · FY2013 · HL · contact PI
Gene Therapy for Long-Term Myocardial Protection$347,421
R01 · FY2013 · HL · contact PI
Gene Therapy for Long-Term Myocardial Protection$588,165
R01 · FY2012 · HL · contact PI
Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury$438,047
R01 · FY2012 · HL · contact PI
Genetically Altered Mesenchymal Stem Cell; Paracrine Effect on Neovascularization$386,100
R01 · FY2012 · HL · contact PI
Gene Therapy for Long-Term Myocardial Protection$561,542
R01 · FY2011 · HL · contact PI
Renin Gene Expression in Cardiovascular Regulation: Mechanisms of JG Hyperplasia$453,522
R01 · FY2011 · HL · contact PI
Genetically Altered Mesenchymal Stem Cell; Paracrine Effect on Neovascularization$390,000
R01 · FY2011 · HL · contact PI
MYOCARDIAL PROTECTION OF HASF IN ACUTE MI$3,068
P41 · FY2011 · RR · contact PI
Renin Gene Expression in Cardiovascular Regulation: Mechanisms of JG Hyperplasia$458,102
R01 · FY2010 · HL · contact PI
Gene Therapy for Long-Term Myocardial Protection$428,146
R01 · FY2010 · HL · contact PI
Genetically Altered Mesenchymal Stem Cell; Paracrine Effect on Neovascularization$390,000
R01 · FY2010 · HL · contact PI
Sfrp2 as a Stem Cell Derived Paracrine Factor for Cardioprotection$526,771
R01 · FY2009 · HL · contact PI
Gene Therapy for Long-Term Myocardial Protection$521,290
R01 · FY2009 · HL · contact PI
Renin Gene Expression in Cardiovascular Regulation: Mechanisms of JG Hyperplasia$453,834
R01 · FY2009 · HL · contact PI
Genetically Altered Mesenchymal Stem Cell; Paracrine Effect on Neovascularization$390,000
R01 · FY2009 · HL · contact PI
Sfrp2 as a Stem Cell Derived Paracrine Factor for Cardioprotection$502,653
R01 · FY2008 · HL · contact PI
Renin Gene Expression in Cardiovascular Regulation: Mechanisms of JG Hyperplasia$440,712
R01 · FY2008 · HL · contact PI
Genetically Altered Mesenchymal Stem Cell; Paracrine Effect on Neovascularization$390,000
R01 · FY2008 · HL · contact PI
Sfrp2 as a Stem Cell Derived Paracrine Factor for Cardioprotection$499,448
R01 · FY2007 · HL · contact PI
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$422,391
R01 · FY2007 · HL · contact PI
Sfrp2 as a Stem Cell Derived Paracrine Factor for Cardioprotection$508,334
R01 · FY2006 · HL · contact PI
GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION$490,752
R01 · FY2006 · HL · contact PI
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$423,230
R01 · FY2006 · HL · contact PI
Homing and Genetic Modification of Mesenchymal Stem Cell$377,173
R01 · FY2006 · HL · contact PI
GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION$490,120
R01 · FY2005 · HL
AT2 RECEPTOR-MEDIATED GENE PROGRAMMING OF SMOOTH MUSCLE$429,132
R01 · FY2005 · HL
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$420,794
R01 · FY2005 · HL
Homing and Genetic Modification of Mesenchymal Stem Cell$385,000
R01 · FY2005 · HL
Homing and Genetic Modification of Mesenchymal Stem Cell$22,589
R01 · FY2005 · HL
GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION$581,512
R01 · FY2004 · HL
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$488,997
R01 · FY2004 · HL
AT2 RECEPTOR-MEDIATED GENE PROGRAMMING OF SMOOTH MUSCLE$419,416
R01 · FY2004 · HL
Homing and Genetic Modification of Mesenchymal Stem Cell$338,505
R01 · FY2004 · HL
Homing and Genetic Modification of Mesenchymal Stem Cell$64,185
R01 · FY2004 · HL
AT2 RECEPTOR-MEDIATED GENE PROGRAMMING OF SMOOTH MUSCLE$46,601
R01 · FY2004 · HL
GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION$17,300
R01 · FY2004 · HL
GENERAL CLINICAL RESEARCH CENTER$5,860,279
M01 · FY2003 · RR
GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION$503,534
R01 · FY2003 · HL
AT2 RECEPTOR-MEDIATED GENE PROGRAMMING OF SMOOTH MUSCLE$435,991
R01 · FY2003 · HL
Homing and Genetic Modification of Mesenchymal Stem Cell$403,558
R01 · FY2003 · HL
GENERAL CLINICAL RESEARCH CENTER$5,563,893
M01 · FY2002 · RR
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$396,871
R37 · FY2002 · HL
AT2 RECEPTOR-MEDIATED GENE PROGRAMMING OF SMOOTH MUSCLE$395,727
R01 · FY2002 · HL
GENERAL CLINICAL RESEARCH CENTER$4,718,488
M01 · FY2001 · RR
GENE TRANSFER PROGRAM IN HEART, LUNG, AND BLOOD DISEASE$1,198,037
P50 · FY2001 · HL
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$387,346
R37 · FY2001 · HL
AT2 RECEPTOR AND VASCULAR DEVELOPMENT$292,034
R01 · FY2001 · HL
CORE--PILOT AND FEASIBILITY STUDIES$219,976
P50 · FY2001 · HL
ENDOTHELIAL CELL TARGETED GENE THERAPY STRATEGIES FOR CORONARY HEART DISEASE$219,976
P50 · FY2001 · HL
GENERAL CLINICAL RESEARCH CENTER$4,689,897
M01 · FY2000 · RR
GENE TRANSFER PROGRAM IN HEART, LUNG, AND BLOOD DISEASE$1,344,772
P50 · FY2000 · HL
RENIN GENE EXPRESSION IN CARDIOVASCULAR REGULATION$378,100
R37 · FY2000 · HL
AT2 RECEPTOR AND VASCULAR DEVELOPMENT$285,158
R01 · FY2000 · HL
CORE--PILOT AND FEASIBILITY STUDIES$277,666
P50 · FY2000 · HL
ENDOTHELIAL CELL TARGETED GENE THERAPY STRATEGIES FOR CORONARY HEART DISEASE$277,666
P50 · FY2000 · HL